Under [the plaintiffs'] reading, virtually all pharmaceutical product-support services would qualify as a kickback,” U.S.

Amjevita (adalimumab-atto) is a prescription drug used for certain inflammatory conditions, including rheumatoid arthritis and ulcerative colitis. Amjevita can cause side effects that range from ...

Both infliximab and adalimumab were found to be effective in achieving remission and enhancing quality of life while having a high level of tolerability in patients with mucocutaneous Behçet ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

Adding methotrexate to adalimumab does not improve treatment effectiveness or durability in adults with plaque psoriasis, according to a study. 1 Findings suggest that adalimumab monotherapy ...

Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

On April 14, 2025, Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to YUFLYMA (adalimumab-aaty), its biosimilar referencing HUMIRA ...

Medically reviewed by Mary Choy, PharmD Biologics work by targeting proteins that cause inflammation in ulcerative colitis. As a result, certain biologics help decrease flare-ups and complications.

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.

Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.